Argus Research Reiterates Buy on Zimmer Biomet Holdings, Maintains $125 Price Target
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsReiterationPrice Target
Argus Research analyst David Toung reiterates Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and maintains $125 price target.
Argus Research analyst David Toung reiterates Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and maintains $125 price target.